Therefore, the physiological activities of the anti-GRP78 antibodies are determined not only by their epitope specificity but also structurally by their core N-glycosylation that either attenuates or enhances its proliferative or apoptotic activities, as observed in cancer and immune diseases. This evidence concerns the gene HSPA5 and cancer.